Food increases the bioavailability of tolterodine but not effective exposure.
The objective of this study was to investigate the influence of food on the pharmacokinetics of tolterodine, its active 5-hydroxymethyl metabolite (5-HM), and exposure to the active moiety (sum of unbound tolterodine + 5-HM) in healthy volunteers. Serum concentrations of tolterodine and 5-HM were measured for up to 12 hours after a single oral dose (2 mg) of tolterodine L-tartrate, administered either on an empty stomach or with a standardized medium-fat breakfast. All 23 subjects completing the study were classified as extensive metabolizers (phenotyped with debrisoquine). Pharmacokinetic data on tolterodine and the active moiety were evaluable for 22 subjects; all completing subjects were evaluable for 5-HM pharmacokinetics. Based on Cmax and AUC(infinity) ratios, relative bioavailability of tolterodine in the presence of food was 1.49 (90% confidence interval [CI], 1.35-1.71) and 1.53 (1.35-1.72), respectively. The pharmacokinetics of 5-HM and the active moiety were unaffected by food, as were the rates of drug absorption and terminal half-lives of tolterodine and 5-HM. Given that bioequivalence was observed for the active moiety underfed and fasting conditions, the authors concluded that coadministration of tolterodine with food is not expected to have any clinically relevant effects.
Olsson
B
B
Department of Clinical Pharmacology, Pharmacia AB, Stockholm, Sweden.
Brynne
N
N
Johansson
C
C
Arnberg
H
H
D000328:Adult; D000704:Analysis of Variance; D019540:Area Under Curve; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D003408:Cresols / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D004435:Eating / Q000502:physiology*; D005215:Fasting / Q000502:physiology*; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate
C109909:5-hydroxymethyl tolterodine; D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; D019389:Cytochrome P-450 CYP2D6